TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11482921

Group type: EXPERIMENTAL
Intervention: Combined use of abciximab and stenting as an adjunct to PTCA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adding a stent to a procedure with abciximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adding abciximab to a stenting procedure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adding abciximab in diabetic patients
Number of subjects: 0
Study: 9683836

Group type: EXPERIMENTAL
Intervention: Ceftazidime + amikacin + teicoplanin (6 mg/kg once a day)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Ceftazidime + amikacin + vancomycin (30 mg/kg/day every 6 h)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Both groups (teicoplanin and vancomycin)
Number of subjects: 106
Study: 7810811

Group type: EXPERIMENTAL
Intervention: Mefloquine (25 mg/kg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Halofantrine (24 mg/kg or 72 mg/kg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Desbutyl-halofantrine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Halofantrine
Number of subjects: 60
Study: 3175849

Group type: EXPERIMENTAL
Intervention: Intracavitary high-dose rate iridium irradiation
Number of subjects: 198

Group type: COMPARATOR
Intervention: Intracavitary radium-226
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Intracavitary high-dose rate iridium irradiation (younger patients)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Intracavitary high-dose rate iridium irradiation (older patients, 70 years and more)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Intracavitary high-dose rate iridium irradiation (tumor grading 1)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Intracavitary high-dose rate iridium irradiation (tumor grading 2 and 3)
Number of subjects: 198
Study: 31953583

Group type: EXPERIMENTAL
Intervention: Positive risk encouragement (e.g., 'You are cool if you continue')
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Negative risk encouragement (e.g., 'You are a softy if you do not continue')
Number of subjects: 356

Group type: COMPARATOR
Intervention: Solo (no peers)
Number of subjects: 356
Study: 28688742

Group type: EXPERIMENTAL
Intervention: Fluvoxamine 50mg/day plus clozapine 100mg/day
Number of subjects: 85

Group type: COMPARATOR
Intervention: Clozapine 300mg/day (monotherapy)
Number of subjects: 85
Study: 27154970

Group type: EXPERIMENTAL
Intervention: Incentivized smoking cessation program
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Self-referrals from media
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Referrals from cessation providers
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Referrals from health professionals
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Contact with participants
Number of subjects: 74
Study: 24773572

Group type: EXPERIMENTAL
Intervention: Memory training program
Number of subjects: 265

Group type: COMPARATOR
Intervention: Health promotion training program
Number of subjects: 265
Study: 22799601

Group type: EXPERIMENTAL
Intervention: home‐based integrated rehabilitation program (progressive resistance strength training, movement strategy training and falls education)
Number of subjects: 180

Group type: COMPARATOR
Intervention: home‐based life skills program (control intervention)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: home‐based integrated rehabilitation program
Number of subjects: 180
Study: 19853334

Group type: EXPERIMENTAL
Intervention: Anterior cruciate ligament substituting design
Number of subjects: 18

Group type: COMPARATOR
Intervention: Traditional curved symmetric articular configuration
Number of subjects: 18
Study: 18076247

Group type: EXPERIMENTAL
Intervention: Short rest between sets (1 minute; SR)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Long rest between sets (4 minutes; LR)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Nontraining control group (CG)
Number of subjects: 21
Study: 16110222

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioural group psychotherapy (20 sessions over 20 weeks)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Routine MMT (control group)
Number of subjects: 73
Study: 12099322

Group type: EXPERIMENTAL
Intervention: Rigid fixation of the maxilla (RMF)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Semirigid fixation of the maxilla (SRMF)
Number of subjects: 42
Study: 8723572

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 600 IU/kg administered intravenously twice weekly for 3 weeks (in conjunction with oral iron supplementation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1691132

Group type: EXPERIMENTAL
Intervention: Cyclic alternating drugs (DNR + VCR + Ara-C)
Number of subjects: 515

Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation (BMT)
Number of subjects: 515
Study: 508556

Group type: EXPERIMENTAL
Intervention: 50 mg three times daily dipyridamole + 180 mg ASA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 75 mg three times daily dipyridamole + 120 mg ASA daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 25 mg dipyridamole three times daily + 60 mg ASA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher doses of dipyridamole and ASA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low doses of ASA in combination with dipyridamole
Number of subjects: 0
Study: 30183431

Group type: EXPERIMENTAL
Intervention: Allied health intervention prioritised for low functioning and complex patients
Number of subjects: 25

Group type: COMPARATOR
Intervention: Current practice prioritising discharge
Number of subjects: 25
Study: 31542747

Group type: EXPERIMENTAL
Intervention: Creatine supplementation in conjunction with resistance training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo in conjunction with resistance training
Number of subjects: 0
Study: 27989693

Group type: EXPERIMENTAL
Intervention: Single dose of artificial tear containing dextran 70 (1mg/ml) and hypromellose (3mg/ml)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Multidose of artificial tear containing 0.3g HPMC and 0.1g of dextran 70 with 0.01% benzalkonium chloride (BAK) as preservative
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Both interventions (Group A and Group B)
Number of subjects: 88
Study: 28682277

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate jet prophylaxis
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (normotensive)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (hypertensive)
Number of subjects: 40
Study: 23645328

Group type: EXPERIMENTAL
Intervention: Prospective ECG-triggered sequential CCTA
Number of subjects: 100

Group type: COMPARATOR
Intervention: Retrospective ECG-gated helical CT
Number of subjects: 100
Study: 21299410

Group type: EXPERIMENTAL
Intervention: Forsus Fatigue Resistant Device (FRD)
Number of subjects: 32
Study: 19723649

Group type: EXPERIMENTAL
Intervention: Lapuleucel-T (APC8024) administered via leukapheresis and infusions in weeks 0, 2, and 4.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lapuleucel-T (APC8024)
Number of subjects: 18
Study: 17536083

Group type: EXPERIMENTAL
Intervention: RCT acceptance group
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: RCT refusal group
Number of subjects: 455

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 455
Study: 15841810

Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum (n = 61)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Chlorhexidine/xylitol/sorbitol chewing gum (n = 55)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Sodium fluoride/xylitol/sorbitol chewing gum (n = 57)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Reference group (no intervention, n = 232)
Number of subjects: 173
Study: 11574740

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 110

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 110

Group type: COMPARATOR
Intervention: Bendrofluazide
Number of subjects: 110

Group type: COMPARATOR
Intervention: Ambulatory Blood Pressure (ABP) measurements
Number of subjects: 110

Group type: COMPARATOR
Intervention: Clinic Blood Pressure (C) measurements
Number of subjects: 110
Study: 10463739

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (nadroparin) - one daily subcutaneous injection, dosage adapted to body-weight
Number of subjects: 130

Group type: COMPARATOR
Intervention: Mechanical prophylaxis (intermittent pneumatic compression)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (nadroparin)
Number of subjects: 130
Study: 7640875

Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation (120 mg single dose or 90 mg daily for 23 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2785260

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) applied to the contralateral leg
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 1
Study: 793500

Group type: EXPERIMENTAL
Intervention: Betahistine hydrochloride
Number of subjects: 30

Group type: COMPARATOR
Intervention: Prochlorperazine maleate
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 30
Study: 30238238

Group type: EXPERIMENTAL
Intervention: Remnant Preservation (RP)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Remnant Debridement (RD)
Number of subjects: 49
Study: 27194545

Group type: EXPERIMENTAL
Intervention: Counseling with care coordination (CCC)
Number of subjects: 606

Group type: COMPARATOR
Intervention: Counseling alone (C)
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: CCC
Number of subjects: 606

Group type: COMPARATOR
Intervention: C
Number of subjects: 606
Study: 25425451

Group type: EXPERIMENTAL
Intervention: Triple therapy (metformin/pioglitazone/exenatide)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Conventional therapy (metformin followed by sulfonylurea and glargine insulin)
Number of subjects: 221
Study: 23171911

Group type: EXPERIMENTAL
Intervention: 10 mg of hydrocortisone orally
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 10 mg of hydrocortisone orally in BPD patients with co-morbid PTSD
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 10 mg of hydrocortisone orally in BPD patients with co-morbid MDD
Number of subjects: 71
Study: 21161466

Group type: EXPERIMENTAL
Intervention: People with melanoma
Number of subjects: 271

Group type: COMPARATOR
Intervention: People never affected by melanoma
Number of subjects: 271
Study: 19811337

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 60
Study: 17105848

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with stenting
Number of subjects: 381

Group type: COMPARATOR
Intervention: Optimal medical therapy alone
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 381

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 381
Study: 15589098

Group type: COMPARATOR
Intervention: Neuroasymptomatic (NAS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: AIDS dementia complex (ADC)
Number of subjects: 100
Study: 11758322

Group type: EXPERIMENTAL
Intervention: Simultaneous bolus injection of 2% lidocaine 2 ml with infusion of propofol
Number of subjects: 80

Group type: COMPARATOR
Intervention: Bolus injection of saline 2 ml, 10 s before propofol infusion
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Bolus injection of lidocaine 2 ml, 10 s before propofol infusion
Number of subjects: 80

Group type: COMPARATOR
Intervention: Bolus injection of saline 2 ml, 10 s before propofol infusion (control group)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Simultaneous bolus injection of lidocaine with propofol
Number of subjects: 80
Study: 9226526

Group type: EXPERIMENTAL
Intervention: Modified formula B (enriched with sodium and potassium), n = 110
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard formula A, n = 254
Number of subjects: 160

Group type: COMPARATOR
Intervention: Mother's milk, n = 50
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Modified formula B, n = 11
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard formula A, n = 23
Number of subjects: 160
Study: 7623170

Group type: COMPARATOR
Intervention: Hackethal nailing
Number of subjects: 40

Group type: COMPARATOR
Intervention: Compression plating
Number of subjects: 40
Study: 2928745

Group type: EXPERIMENTAL
Intervention: Candida original mouthrinse (1508 ppm F)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: AmF/SnF2 mouthrinse (241 ppm F)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Candida reduced mouthrinse (330 ppm F)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ZH mouthrinse (287 ppm F)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Act mouthrinse (308 ppm F)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Candida original and ZH mouthrinses
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: AmF/SnF2 and Act mouthrinses
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All mouthrinses
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mouthrinses after monofluorophosphate dentifrice
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rinsing with test agents after brushing with amine fluoride dentifrice (Elmex)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: In-between meals
Number of subjects: 12
Study: 30756370

Group type: EXPERIMENTAL
Intervention: Nutritional nursing intervention based on glycemic load (GL)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Conventional nutritional nursing
Number of subjects: 134
Study: 28525984

Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus Fermentum CECT5716, daily for 8 weeks
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo, daily for 8 weeks
Number of subjects: 600
Study: 26573042

Group type: EXPERIMENTAL
Intervention: Home-based cardiac rehabilitation programs
Number of subjects: 110

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 110
Study: 23149845

Group type: EXPERIMENTAL
Intervention: Group B therapy (FAB/LMB 96 study)
Number of subjects: 42

Group type: COMPARATOR
Intervention: non-MLBL DLBCL
Number of subjects: 42
Study: 21685808

Group type: EXPERIMENTAL
Intervention: Total Body Load (TBL) obtained from GPS devices
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Session Rating of Perceived Exertion (session-RPE)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Small-sided games training sessions
Number of subjects: 22
Study: 18285717

Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha-2b plus Ribavirin
Number of subjects: 87

Group type: COMPARATOR
Intervention: Non-cirrhotic patients
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Cirrhotic patients not responding or relapsing after treatment
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Cirrhotic patients with SVR
Number of subjects: 87
Study: 16855066

Group type: EXPERIMENTAL
Intervention: Tennis specific fitness test (FT)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Treadmill test (TT)
Number of subjects: 9
Study: 15256823

Group type: EXPERIMENTAL
Intervention: Peritoneal closure (group I)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Peritoneal non-closure (group II)
Number of subjects: 54
Study: 10637531

Group type: EXPERIMENTAL
Intervention: VOCs at 25 mg/m(3) for four hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VOCs at 50 mg/m(3) for four hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Filtered air for four hours
Number of subjects: 0
Study: 9310806

Group type: EXPERIMENTAL
Intervention: Hemofiltration
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no hemofiltration)
Number of subjects: 28
Study: 8317063

Group type: EXPERIMENTAL
Intervention: Oral intake of a polyethylene glycol solution (out-patient)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Oral intake of a polyethylene glycol solution (in-patient)
Number of subjects: 199
Study: 2446061

Group type: EXPERIMENTAL
Intervention: Ketanserin (40 mg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Ketanserin (40 mg) plus Hydrochlorothiazide (25 mg)
Number of subjects: 21
Study: 30325939

Group type: EXPERIMENTAL
Intervention: AL-335 800 mg QD in non-cirrhotic, GT1-4-infected subjects
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: AL-335 800 mg QD in GT1-infected cirrhotic subjects
Number of subjects: 112

Group type: COMPARATOR
Intervention: AL-335 (100-1,200 mg) in healthy volunteers
Number of subjects: 112

Group type: COMPARATOR
Intervention: AL-335 (400, 800, 1,200 mg) in HCV-infected subjects
Number of subjects: 112

Group type: COMPARATOR
Intervention: AL-335 (400 mg) in fed state
Number of subjects: 112

Group type: COMPARATOR
Intervention: AL-335 (1,200 mg) in fasted state
Number of subjects: 112
Study: 28391393

Group type: EXPERIMENTAL
Intervention: NZBC extract 600 mg day-1
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: NZBC extract 900 mg day-1
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: NZBC extract 300 mg day-1
Number of subjects: 15

Group type: COMPARATOR
Intervention: No dose
Number of subjects: 15
Study: 26052874

Group type: EXPERIMENTAL
Intervention: Clinician feedback intervention (CCFS) consisting of weekly performance feedback to clinicians and a clinical feedback report.
Number of subjects: 100

Group type: COMPARATOR
Intervention: No feedback condition (control group).
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Clinician feedback intervention (CCFS)
Number of subjects: 100
Study: 23411609

Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg daily
Number of subjects: 969
Study: 22332579

Group type: EXPERIMENTAL
Intervention: Oral glucosamine hydrochloride (1.44 g daily) + intraarticular hyaluronate injection
Number of subjects: 28
Study: 18643006

Group type: EXPERIMENTAL
Intervention: Induced subordinate status
Number of subjects: 44

Group type: COMPARATOR
Intervention: Induced dominant status
Number of subjects: 44
Study: 16801645

Group type: EXPERIMENTAL
Intervention: Bilateral STN stimulation
Number of subjects: 103
Study: 14580925

Group type: EXPERIMENTAL
Intervention: BAY 19-8004 (5 mg once daily)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 10911768

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Nutrition intervention
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Both nutrition intervention and exercise
Number of subjects: 159
Study: 8810971

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Antacid
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 242
Study: 1389989

Group type: EXPERIMENTAL
Intervention: Thymostimulin
Number of subjects: 212

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 212
Study: 6380253

Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 30
Study: 30977496

Group type: EXPERIMENTAL
Intervention: Fish oil (FO)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Flaxseed oil (FSO)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (Corn oil, CO)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Correlation with metabolic risk factors
Number of subjects: 59
Study: 29526243

Group type: EXPERIMENTAL
Intervention: Standard cancer treatment plus the ANITA program (integrative Tai Chi program including peer support, health education, and Tai Chi Ruler exercise)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard cancer treatment alone
Number of subjects: 24
Study: 27154310

Group type: EXPERIMENTAL
Intervention: Merozoite antigens (specifically Rh5 codons 147 and 148)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Asymptomatic malaria infections
Number of subjects: 0

Group type: COMPARATOR
Intervention: Complicated malaria infections
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All three malaria infection populations (uncomplicated, asymptomatic, complicated)
Number of subjects: 0
Study: 25980150

Group type: EXPERIMENTAL
Intervention: Nasal packing with pulmicort respules combined with nasopore after surgery
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nasal packing with only nasopore after surgery
Number of subjects: 30
Study: 22648913

Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg (test formulation)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Pentoxifylline 400 mg (reference formulation)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 24
Study: 20478402

Group type: EXPERIMENTAL
Intervention: n‐acetylcysteine pretreatment before a culture‐guided antibiotic regimen
Number of subjects: 40

Group type: COMPARATOR
Intervention: No n‐acetylcysteine pretreatment (control group)
Number of subjects: 40
Study: 17628824

Group type: EXPERIMENTAL
Intervention: Oral administration of sodium bicarbonate (NaHCO3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral administration of calcium carbonate (CaCO3)
Number of subjects: 0
Study: 16131376

Group type: EXPERIMENTAL
Intervention: Photochemically treated apheresis platelets (PCT)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Conventional apheresis platelets (reference)
Number of subjects: 43
Study: 12027195

Group type: EXPERIMENTAL
Intervention: Delirium-free protocol (DFP) group with diazepam injection at 20:00 h and continuous infusion of flunitrazepam and pethidine for 8 hours for the first three nights postoperatively
Number of subjects: 42

Group type: COMPARATOR
Intervention: Non-DFP group
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Delirium-free protocol (DFP) group
Number of subjects: 42
Study: 10030314

Group type: EXPERIMENTAL
Intervention: Same-day screening mammography availability
Number of subjects: 920

Group type: COMPARATOR
Intervention: Usual screening mammography scheduling
Number of subjects: 920
Study: 7560363

Group type: EXPERIMENTAL
Intervention: Sugarless chewing gums (sweetened with sucrose, aspartame, saccharin, acesulfame-K, or xylitol)
Number of subjects: 8

Group type: COMPARATOR
Intervention: No gum
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sucrose gum
Number of subjects: 8
Study: 2286596

Group type: EXPERIMENTAL
Intervention: Ofloxacin (200 mg bd, intravenous for 3 days followed by oral for 7-10 days)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Amoxycillin/clavulanate (intravenous for 3 days followed by oral for 7-10 days)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 121

Group type: COMPARATOR
Intervention: Amoxycillin/clavulanate
Number of subjects: 121